Telisotuzumab Adizutecan

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of a monoclonal antibody against the tumor-associated antigen (TAA) proto-oncogene c-Met (hepatocyte growth factor receptor; HGFR) linked to adizutecan, a camptothecin derivative and topoisomerase inhibitor, with potential antineoplastic activity. Upon intravenous administration of anti-c-Met ADC ABBV-400, the monoclonal antibody moiety targets and binds to c-Met expressed on tumor cells. Upon binding and internalization, adizutecan is released, which binds to and inhibits topoisomerase, thereby inhibiting DNA replication and killing the c-Met-expressing cancer cells. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis and tumor angiogenesis.

**Synonyms:** - ABBV 400 - ABBV-400 - ABBV400 - ADC ABBV-400 - Anti-c-Met ADC ABBV-400 - Anti-c-Met Antibody-drug Conjugate ABBV-400 - TELISOTUZUMAB ADIZUTECAN - c-Met ADC ABBV-400